LMO3 and diffuse large B-cell lymphoma: In a subgroup of patients with CD5− ABC DLBCL, SH3BP5 was positive in 58% (19 of 33), with LMO3 positive in 11% (four of 37) and SNAP25 positive in 41% (12 of 29).